Investigating how a cancer protein disrupts normal cell functions in Ewing sarcoma
Official title: Structural and mechanistic investigation into EWS::FLI1 disruption of EWS function in transcription and DNA repair
Funded at University of Texas Hlth Science Center · NIH-10997560 · Data updated 2026-11-12
This study is looking at how a specific protein involved in Ewing sarcoma, a type of cancer in kids, affects the way cells work and how they respond to treatments, with the goal of finding better ways to help young patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $38,363 |
| NIH project number | 1F31CA295030-01 |
| Project ID | NIH-10997560 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children and adolescents diagnosed with Ewing sarcoma.
✕Less likely to help
Patients with other types of cancers or those without Ewing sarcoma may not benefit from this research.
What this research studies
This research focuses on Ewing sarcoma, a type of pediatric cancer caused by a genetic fusion that creates a problematic protein called EWS::FLI1. This protein disrupts the normal functions of another protein, EWS, which is crucial for DNA repair and transcription processes in cells. By understanding the molecular interactions between EWS and EWS::FLI1, the research aims to uncover how this disruption leads to cancer progression and sensitivity to certain treatments. The approach includes biochemical assays and cellular models to study these interactions in detail.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating Ewing sarcoma by targeting the mechanisms of EWS::FLI1.
How similar studies have gone: Previous research has shown promising results in understanding similar oncogenic fusion proteins and their roles in cancer, suggesting potential for success in this area as well.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Sohn, Erich — University of Texas Hlth Science Center
- Study coordinator: Sohn, Erich
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.